Mitotane - Revision history

Prab at 20:08, 21 March 2025

2025-03-21T20:08:22Z

← Older revision		Revision as of 20:08, 21 March 2025
Line 1:		Line 1:
			[[File:Mitotane.svg\|Mitotane\|thumb]]
			[[File:Mitotane-(2S)-enantiomer-from-xtal-3D-bs-17.png\|Mitotane (2S)-enantiomer\|thumb]]
	{{intro}}		{{intro}}
	Omacetaxine is a semisynthetic cephataxine that acts as a protein translation inhibitor and is used to treated chronic myeloid [[leukemia]] that is resistant to tyrosine kinase receptor antagonists.		Omacetaxine is a semisynthetic cephataxine that acts as a protein translation inhibitor and is used to treated chronic myeloid [[leukemia]] that is resistant to tyrosine kinase receptor antagonists.
Line 12:		Line 14:
	{{se}}		{{se}}
	Common [[side effects]] include myelosuppression which can be severe, injection site reactions, [[diarrhea]], [[fatigue]], weakness, [[nausea]], [[headache]], pyrexia and infections. Uncommon, but potentially severe adverse events include neutropenic [[fever]] and sepsis, cerebral hemorrhage and hyperglycemia.		Common [[side effects]] include myelosuppression which can be severe, injection site reactions, [[diarrhea]], [[fatigue]], weakness, [[nausea]], [[headache]], pyrexia and infections. Uncommon, but potentially severe adverse events include neutropenic [[fever]] and sepsis, cerebral hemorrhage and hyperglycemia.
			{{Chemotherapeutic agents}}
	{{~~cancer drugs~~}}		{{Glucocorticoids and antiglucocorticoids}}
	{{~~coststubd~~}}		{{Portal bar \| Medicine}}
	~~<gallery>~~		[[Category:3β-Hydroxysteroid dehydrogenase inhibitors]]
	~~File~~:~~Mitotane.svg\|Mitotane~~		[[Category:11β-Hydroxylase inhibitors]]
	~~File~~:~~Mitotane-(2S)-enantiomer-from-xtal-3D-bs-17.png\|Mitotane (2S)~~-~~enantiomer~~		[[Category:Aldosterone synthase inhibitors]]
	~~</gallery>~~		[[Category:Antiglucocorticoids]]
	~~== Mitotane ==~~		[[Category:Antineoplastic drugs]]
	~~<gallery>~~		[[Category:Cholesterol side-chain cleavage enzyme inhibitors]]
	~~File~~:~~Mitotane.svg\|Mitotane~~		[[Category:CYP3A4 inducers]]
	~~File~~:~~Mitotane~~-~~(2S)-enantiomer-from-xtal-3D~~-~~bs-17.png\|Mitotane (2S)-enantiomer~~		[[Category:Organochlorides]]
	~~</gallery>~~		[[Category:Orphan drugs]]
			[[Category:Steroidogenesis inhibitors]]
			[[Category:2-Chlorophenyl compounds]]
			[[Category:4-Chlorophenyl compounds]]

Prab: CSV import

2025-02-20T01:26:49Z

CSV import

← Older revision		Revision as of 01:26, 20 February 2025
Line 15:		Line 15:
	{{cancer drugs}}		{{cancer drugs}}
	{{coststubd}}		{{coststubd}}
			<gallery>
			File:Mitotane.svg\|Mitotane
			File:Mitotane-(2S)-enantiomer-from-xtal-3D-bs-17.png\|Mitotane (2S)-enantiomer
			</gallery>
			== Mitotane ==
	<gallery>		<gallery>
	File:Mitotane.svg\|Mitotane		File:Mitotane.svg\|Mitotane
	File:Mitotane-(2S)-enantiomer-from-xtal-3D-bs-17.png\|Mitotane (2S)-enantiomer		File:Mitotane-(2S)-enantiomer-from-xtal-3D-bs-17.png\|Mitotane (2S)-enantiomer
	</gallery>		</gallery>

Prab: CSV import

2025-02-20T01:21:17Z

CSV import

← Older revision		Revision as of 01:21, 20 February 2025
Line 15:		Line 15:
	{{cancer drugs}}		{{cancer drugs}}
	{{coststubd}}		{{coststubd}}
			<gallery>
			File:Mitotane.svg\|Mitotane
			File:Mitotane-(2S)-enantiomer-from-xtal-3D-bs-17.png\|Mitotane (2S)-enantiomer
			</gallery>

Prab: Created page with "{{intro}} Omacetaxine is a semisynthetic cephataxine that acts as a protein translation inhibitor and is used to treated chronic myeloid leukemia that is resistant to tyro..."

2019-04-19T18:48:48Z

Created page with "{{intro}} Omacetaxine is a semisynthetic cephataxine that acts as a protein translation inhibitor and is used to treated chronic myeloid leukemia that is resistant to tyro..."

New page

{{intro}}
Omacetaxine is a semisynthetic cephataxine that acts as a protein translation inhibitor and is used to treated chronic myeloid [[leukemia]] that is resistant to tyrosine kinase receptor antagonists.

{{livtox}}
Omacetaxine is associated with a low rate of serum enzyme elevation during therapy, but has not been linked to cases of clinically apparent [[liver injury]] with jaundice.

{{moa}}
Omacetaxine (oh" ma se tax' een) mepesuccinate is a semisynthetic molecule previously known as homoharringtonine which is derived from the leaves and bark of Cephalotaxus harringionia (plum yew). Omacetaxine is an inhibitor of protein translation which binds to ribosomes and blocks the initial elongation step in the synthesis of proteins from m[[RNA]]. Therapy with omacetaxine was found to have activity against chronic myeloid [[leukemia]] (CML) and was considered a first line agent before the introduction of the tyrosine kinase inhibitor imatinib. More recently, omacetaxine has found to improve survival in patients with refractory CML and resistance to multiple tyrosine kinase inhibitors and was approved for this use in the United States in 2012.

Omacetaxine is administered parenterally and is available in single use vials of 3.5 mg of lyophilized powder for reconstitution. The recommended dose is 1.25 mg/m2 injected subcutaneously twice daily on days 1 to 14 of 28-day cycles, with subsequent modification once remission is achieved to twice daily on days 1 to 7 of 28-day cycles.

{{se}}
Common [[side effects]] include myelosuppression which can be severe, injection site reactions, [[diarrhea]], [[fatigue]], weakness, [[nausea]], [[headache]], pyrexia and infections. Uncommon, but potentially severe adverse events include neutropenic [[fever]] and sepsis, cerebral hemorrhage and hyperglycemia.

{{cancer drugs}}
{{coststubd}}